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ABSTRACT
Introduction: The objective of this study was to
compare the clinical effectiveness of liraglutide
with sitagliptin and assess the associated
economic outcomes in patients with type 2
diabetes mellitus (T2DM) treated in real-world
practice in the United States (US).
Methods: This retrospective cohort study used
a large US claims database to identify patients
with T2DM who initiated liraglutide or
sitagliptin between January 2010 and
December 2012. Adults (C18 years old) with
persistent use of therapy for C3 months were
included. Changes in glycated hemoglobin A1c
(A1C) and the proportion of patients achieving
A1C targets (B6.5% and\7%) were examined at
6-month follow-up. Diabetes-related total,
medical, and pharmacy costs over the follow-up
period were assessed. Multivariable regression
models were used to estimate the outcomes
associated with liraglutide relative to sitagliptin,
adjusting for differences in patient
demographics and clinical characteristics.
Results: The study included 1,465 patients with
T2DM who initiated liraglutide (N = 376) or
sitagliptin (N = 1,089) (mean age [standard
deviation (SD)]: 54 [8.9] vs. 58 [10.8] years;
43.9% vs. 61.8% males; both P\0.01). After
controlling for confounding factors, liraglutide
patients experienced 0.31% points greater
reduction in A1C (0.95% vs. 0.63% points;
P\0.01) at 6-month follow-up than sitagliptin
patients and were more likely to reach A1C
targets of B6.5% (odds ratio [OR]: 2.00;
P\0.01) and \7% (OR: 1.55; P\0.01).
Liraglutide patients had $994 lower mean
diabetes-related medical costs ($1,241 vs.
$2,235; P\0.01), but $544 higher diabetes-
related pharmacy costs ($2,100 vs. $1,556;
P\0.01) during the follow-up. No difference
was found in the total mean diabetes-related
costs between the two cohorts.
Conclusion: Liraglutide showed greater
improvement in glycemic outcomes than
sitagliptin among adult patients with T2DM in
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real-world clinical practice. Although diabetes-
related pharmacy costs for patients using
liraglutide were higher compared with
sitagliptin, these were offset by significantly
lower diabetes-related medical costs, resulting
in similar total diabetes-related costs between
the two treatment groups.
Keywords: Clinical effectiveness; Comparative
effectiveness; Costs; Glycated hemoglobin A1c
(A1C); Liraglutide; Sitagliptin; Type 2 diabetes
mellitus
INTRODUCTION
Diabetes affects more than 8.3% of the total
population and is the seventh leading cause of
death in the United States (US) [1]. The total
estimated direct and indirect costs of treating
diabetes in the US were $176 billion and $69
billion, respectively, in 2012 [2]. Type 2 diabetes
mellitus (T2DM) accounts for 90–95% of all
diagnosed cases of diabetes [1].
The key to managing diabetes is optimal
glycemic control, while minimizing the risk of
experiencing hypoglycemia, which is associated
with significant reduction in the development
of microvascular and macrovascular
complications [3–5]. While lifestyle
modifications such as healthy eating and
exercise can help control glycemia,
pharmacological agents remain the
mainstream treatment to maintain target
glucose levels, especially due to the progressive
nature of diabetes. Incretin-based therapies for
the management of T2DM are effective in
lowering glycated hemoglobin A1c (A1C) with
a low risk of hypoglycemia [6–8]. These
therapies, including injectable glucagon-like
peptide-1 (GLP-1) receptor agonists (such as
liraglutide [Victoza; Novo Nordisk A/S,
Bagsvaerd, Denmark]) and oral dipeptidyl
peptidase-4 (DPP-4) inhibitors (such as
sitagliptin [Januvia; Merck Sharp & Dohme
Corp., Whitehouse Station, NJ, USA]), have
different mechanisms of actions in increasing
insulin secretion and decreasing glucagon
secretion [9].
Head-to-head trials of liraglutide versus
sitagliptin have shown that liraglutide is
superior to sitagliptin for glycemic control and
weight loss [10–12]. Patients on liraglutide also
reported greater treatment satisfaction than
those using sitagliptin [13]. However, there are
few studies assessing the real-world comparative
effectiveness of these drugs. The economic
implication of the clinical effectiveness of
liraglutide versus sitagliptin is unknown in the
US. This study aims to address this knowledge
gap by comparing the real-world clinical and
economic outcomes among persistent




This retrospective observational study utilized
data from the Truven Health MarketScan
(Truven Health Analytics Inc., Ann Arbor, MI,
USA) Commercial and Medicare Supplemental
Insurance Databases. The databases contain
administrative claims and eligibility records for
over 30 million commercially insured
individuals (i.e., working age adults and their
dependents) and 3 million enrollees in
Medicare supplemental plans. The data
represent the healthcare experience of
employees, dependents, and retirees with
primary or Medicare supplemental coverage
through privately insured health plans. In
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addition, the Truven Health MarketScan Lab
database, which contains 32.6 million lab test
results for approximately 1.9 million unique
privately insured patients, was linked to the
healthcare claim databases on a patient level.
Data from July 2009 through December 2012
were used in this study. This article does not
contain any new studies with human or animal
subjects performed by any of the authors.
Sample Selection
The study sample included patients who filled
prescriptions for either liraglutide or sitagliptin
between January 1, 2010 and December 31,
2012. The first pharmacy claim for liraglutide or
sitagliptin defined the index therapy and the
index date. Patients were required to be at least
18 years of age at the index date and have
continuous health plan enrollment for at least
6 months prior to (washout period) and
6 months after (follow-up period) the index
date. Patients were excluded if they (1) filled a
prescription for any GLP-1 receptor agonists or
any DPP-4 inhibitors during the washout
period, (2) had type 1 diabetes (International
Classification of Diseases, 9th Revision, Clinical
Modification [ICD-9-CM] codes: 250.x1 or
250.x3), polycystic ovarian syndrome (ICD-9-
CM code 256.4), pregnancy, or gestational
diabetes during the washout or follow-up
period.
The study analyzed outcomes from patients
who continuously used the index therapy for at
least 3 months (i.e., persistent users) to reduce
the potential confounding from the use of other
medications [14]. Treatment discontinuation
was defined as a period of at least 90
consecutive days without a prescription fill of
the index therapy. Persistent patients with at
least one A1C measure in 45 days prior to 7 days
after the index date and at least one A1C
measure in ±45 days around the end of
6-month follow-up period were considered.
Demographic and Clinical Characteristics
Demographic characteristics assessed were age,
gender, geographic region (Northeast, North
Central, South, and West), metropolitan area
status, health plan type (i.e., health
maintenance organization, preferred provider
organization, and others), and index year of
treatment initiation. Baseline clinical
characteristics included type of provider for
the index therapy (primary care physician,
endocrinologists, and other types) and several
measures identified over the 6-month washout
period: Charlson Comorbidity Index adapted to
predict healthcare costs [15], the occurrence of
common diabetes-related complications and
comorbidities (retinopathy, nephropathy,
neuropathy, cerebrovascular, cardiovascular,
peripheral vascular disease, depression, obesity,
hypertension, and hyperlipidemia) identified
via ICD-9-CM codes [16], use of oral
anti-diabetics (metformin, sulfonylurea,
thiazolidione, and others) and insulin, and
occurrence of severe hypoglycemia. Severe
hypoglycemic events were identified by both
ICD-9-CM codes [17] and recorded fasting
plasma glucose level of less than or equal to
40 mg/dL [18].
Clinical and Economic Outcomes
Glycemic outcomes at 6 months of follow-up
were measured by the following clinical
endpoints: absolute change in A1C from
baseline and A1C goal attainment of B6.5%
and \7% as recommended by the American
Association of Clinical Endocrinologists [19]
and American Diabetes Association [20],
respectively. The follow-up A1C measure was
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defined as the value closest to day 180 post-
index within a ±45-day window, while baseline
A1C was defined as the value closest to the
index date within a window of 45 days prior to
7 days after the index date.
Economic outcomes assessed were total
healthcare costs related to T2DM over the
6 months of follow-up, stratified by diabetes-
related medical costs and pharmacy costs for
anti-diabetic medications. These costs were
identified from medical claims with a primary
or secondary diagnosis code for diabetes (ICD-9-
CM 250.xx), and pharmacy claims for oral anti-
diabetic medication, non-insulin injectables
(exenatide or liraglutide), and insulin. All costs
were adjusted to 2013 values based on
Consumer Price Index Medical Component
[21].
Statistical Analysis
The study measures between treatment groups
were compared using Student’s t test, Chi-
square test, and Wilcoxon rank-sum test for
continuous, categorical, and cost variables,
respectively. Multivariable regression models
were used to assess the association between
the index therapy (liraglutide or sitagliptin) and
the outcomes. The model specifications were
based on the distribution of the outcomes.
Absolute changes in A1C were assessed using
ordinary least square regression, A1C goal
attainment was assessed using logistic
regression, and economic outcomes (total,
medical, and pharmacy costs related to T2DM)
were assessed using generalized linear models
with a log link and gamma distribution. All
regression models adjusted for baseline patient
characteristics, including demographics and
clinical characteristics, baseline A1C, and total
healthcare costs related to T2DM during the
6-month washout period. Adjusted ratios of the
outcomes associated with liraglutide and with
sitagliptin were reported, including the odds
ratio (OR) for the A1C goal attainment and the
cost ratio (CR) for the economic outcomes.
Adjusted values of the outcomes were calculated
from the regression results using the method of
recycled predictions, in which the adjusted
outcomes were predicted twice for each
patient in the sample, once assuming
liraglutide and the other time assuming
sitagliptin as the index therapy, respectively
[22]. Data were compiled and analyzed using
SAS (version 9.4, SAS Institute Inc., Cary, NC).
RESULTS
A total of 444,651 adults filled prescriptions for
liraglutide or sitagliptin between January 1,
2010 and December 31, 2012. After applying
inclusion/exclusion criteria, the final study
sample included 1,465 patients with baseline
and follow-up A1C measures, of whom 376 were
liraglutide patients and 1,089 were sitagliptin
patients (Fig. 1). Patients initiating liraglutide
differed significantly from those initiating
sitagliptin in terms of characteristics.
Liraglutide patients were younger (mean age
[standard deviation (SD)]: 54 [8.9] years vs. 58
[10.8] years; P\0.01) and were less likely to be
males (43.9% vs. 61.8%; P\0.01) than
sitagliptin patients (Table 1). Liraglutide
patients were more likely to obtain their
prescriptions from endocrinologists than
sitagliptin patients (15.7% vs. 4.4%; P\0.01;
Table 2). In addition, patients initiating
liraglutide were less likely to have
cardiovascular diseases (7.5% vs. 12.2%;
P = 0.01) or nephropathy (4.8% vs. 8.2%;
P = 0.03), less likely to use sulfonylurea (33.2%
vs. 49.8%; P\0.01), but more likely to use
insulin during the washout period (35.4% vs.
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16.9%; P\0.01). Liraglutide patients had lower
A1C (mean [SD]: 7.90% [1.7] vs. 8.18% [1.6];
P\0.01) and lower total T2DM-related costs
($1,589 [2,784] vs. $2,049 [6,646]; P\0.01)
than sitagliptin patients at baseline. The
baseline pharmacy costs for anti-diabetic
medication were similar between the two
groups.
Unadjusted outcomes for liraglutide patients
were more favorable than for sitagliptin
patients. Liraglutide patients experienced
higher A1C reductions at 6-month follow-up
(0.85% points [1.5] vs. 0.66% points [1.5];
P = 0.04) and were more likely to reach targets
of A1C B6.5% (41.7% vs. 24.4%; P\0.01) and
A1C\7.0% (56.4% vs. 42.1%; P\0.01; Table 3)
than sitagliptin patients. Liraglutide patients
also had lower total T2DM-related costs
($3,114 [4,029]) vs. $3,784 [9,251]); P\0.01)
than sitagliptin patients over the 6 months of
follow-up despite higher pharmacy costs for
anti-diabetic medication ($2,016 [1,547] vs.
$1,580 [978]; P\0.01).
Multivariable regression models were used to
adjust for differences in baseline patient
characteristics, including demographic and
clinical characteristics, baseline A1C, and total
healthcare costs related to T2DM during the
6-month washout period. These regression
results were then used to predict the adjusted
outcomes. The adjusted reduction of A1C at
6-month follow-up from baseline was predicted
to be on average 0.31% points higher for
liraglutide patients than sitagliptin patients
(0.95% points vs. 0.63% points; P\0.01;
Table 4). Correspondingly, a higher proportion
Fig. 1 Sample selection. A1C Glycated hemoglobin A1c, GLP-1 glucagon-like peptide-1, DPP-4 dipeptidyl peptidase-4
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of liraglutide patients achieved of a target A1C
B6.5% (OR: 2.00; P\0.01) as well as target A1C
\7% (OR: 1.55; P\0.01) than sitagliptin
patients at 6-month follow-up. Adjusted
T2DM-related medical costs were 44% lower
(CR: 0.56; P\0.01) and pharmacy costs were
35% higher (CR: 1.35; P\0.01) for liraglutide
patients than for sitagliptin patients. Adjusted
T2DM-related medical costs were $994 lower
($1,241 vs. $2,235; P\0.01) and adjusted
pharmacy costs were $544 higher ($2,100 vs.
$1,556; P\0.01) for liraglutide patients than
for sitagliptin patients. The difference in the
adjusted total diabetes-related costs was not
statistically significant between the two
therapies. Few other demographic and clinical
characteristics were also statistically
significantly associated with the clinical and
economic outcomes (see the Appendix in
electronic supplementary material).
DISCUSSION
This is the first study to provide integrated
evidence on the clinical effectiveness and the
associated economic impact of treatment with
liraglutide versus sitagliptin in real-world
clinical practice in the US. In this intent-to-
treat study, multivariable regressions were used
to adjust for the differences in baseline patient
demographics (such as age and gender) and
clinical characteristics (such as baseline A1C
level and diabetes-related costs) between
patients initiating liraglutide and sitagliptin.
Liraglutide patients showed significantly greater
reduction in A1C and were more likely to
achieve A1C targets than sitagliptin patients at
6 months of follow-up. The improved glycemic
control associated with liraglutide compared
with sitagliptin had economic implications.
Despite higher pharmacy costs, liraglutide
patients had significantly lower medical costs
related to the management of T2DM over the
6 months follow-up compared with sitagliptin
Table 1 Baseline demographics






54 (8.9) 58 (10.8) \0.01






Male (%) 43.9 61.8 \0.01











North Central 8.8 11.4
South 60.9 32.4
West 14.9 37.0
Metropolis area (%) 89.4 95.6 \0.01





* P values were determined using t tests for continuous
variables, and the Chi-square test for categorical variables,
to assess statistical signiﬁcance
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patients. No significant difference was found in
the total diabetes-related costs between the
treatment groups.
The clinical results of this study are
consistent with the previously published
findings from real-world practice. The study by
Lee et al. [23] compared glycemic outcomes at
6 months of follow-up among adult patients
with T2DM who initiated liraglutide, exenatide,
or sitagliptin. Their study demonstrated that
liraglutide patients had 0.40% points greater
reduction in mean A1C (1.08% points vs. 0.68%
points; P\0.01) and a higher proportion
attaining A1C target of \7% (64.4% vs. 49.4%;
P\0.01) at 6 months of follow-up than
sitagliptin patients [23]. Another study, based
on T2DM patients who were treated with at
least 3 months of incretin-based therapies in





















Retinopathy 4.8 5.3 0.68
Nephropathy 4.8 8.2 0.03
Neuropathy 6.7 6.7 0.97
Cerebrovascular 1.3 2.4 0.22




Depression 2.9 2.4 0.57
Obesity 1.6 1.6 0.96
Hypertension 28.7 27.7 0.71
Hyperlipidemia 22.3 19.7 0.28
Use of anti-diabetic medications (%)
Metformin 56.1 57.8 0.58
Sulfonylurea 33.2 49.8 \0.01
Thiazolidione 18.6 23.1 0.07
Other OADs 2.7 2.2 0.61










Liraglutide Sitagliptin P value*














Diabetes-related pharmacy costs (US dollars)




A1C Glycated hemoglobin A1c, OAD oral anti-diabetic
drug, SD standard deviation
* P values were determined using t tests for continuous
variables, the Chi-square test for categorical variables, and
Wilcoxon rank-sum test for cost variables, to assess
statistical signiﬁcance
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Wales, UK, reported that the reduction in mean
A1C from baseline was 0.44% points greater
(1.23% points vs. 0.79% points; P\0.05)
among patients using liraglutide versus those
using DPP-4 inhibitors [24].
The results from our real-world study
support the trial findings that liraglutide is
superior to sitagliptin in improving glycemic
outcomes [10–12, 25]. Our study showed that
patients with T2DM who initiated liraglutide
had a greater reduction in A1C and a higher
proportion of patients attained A1C targets of
B6.5% and \7% compared with patients who
initiated sitagliptin. A recent randomized
parallel-group, open-label clinical trial
compared the efficacy and safety of liraglutide
versus sitagliptin at 26 weeks of treatment
among adults with T2DM with inadequate
glycemic control on metformin (N = 665;
mean baseline A1C: 8.5%) [11]. In this trial,
mean A1C reductions for liraglutide 1.2 mg
(1.24% points) and 1.8 mg (1.50% points) were
superior to those of sitagliptin (0.90% points)
(both P\0.01 compared with sitagliptin). A
26-week extension yielded similar results, with
mean A1C reductions of 1.29% points, 1.51%
points, and 0.88% points, respectively (both
P\0.01 compared with sitagliptin) [10]. The
efficacy of liraglutide in this clinical trial, in
terms of absolute mean reduction in A1C, is
slightly higher than the clinical effectiveness
found in our study (0.95% points adjusted
mean reduction in A1C at 6-month follow-up)
but the relative treatment effects of liraglutide
versus sitagliptin are comparable. The higher
absolute reduction in A1C associated with
Table 3 Descriptive, unadjusted clinical and economic outcomes at 6-month follow-up
Outcome Liraglutide Sitagliptin P value*
Number of patients (N) 376 1,089
Clinical outcomes
Absolute change in A1C, % points: mean (SD) -0.85 (1.5) -0.66 (1.5) 0.04
A1C B6.5% 41.7% 24.4% \0.01
A1C\7.0% 56.4% 42.1% \0.01
Economic outcomes
Total diabetes-related costs (US dollars)
Mean (SD) $3,114 (4,029) $3,784 (9,251) \0.01
Median $2,401 $1,881
Diabetes-related medical costs (US dollars)
Mean (SD) $1,098 (3,731) $2,204 (9,205) 0.99
Median $300 $298
Pharmacy costs of anti-diabetics (US dollars)
Mean (SD) $2,016 (1,547) $1,580 (978) \0.01
Median $1,865 $1,448
A1C Glycated hemoglobin A1c, SD standard deviation
* P values were determined using t tests for continuous variables, the Chi-square test for categorical variables, and Wilcoxon
rank-sum test for cost variables, to assess statistical signiﬁcance
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liraglutide in the clinical trial than in the
current real-world study may reflect the
stricter settings in clinical trials in terms of
patient adherence and monitoring.
The greater improvement in clinical
response associated with liraglutide versus
sitagliptin may be linked to a lower economic
burden in the treatment of T2DM. This study
showed that savings in diabetes-related medical
costs associated with the use of liraglutide offset
the higher pharmacy costs of liraglutide. The
economic outcomes in this study were assessed
directly from insurance claims, and payment of
the medical services and pharmacy
prescriptions paid by the individual patients or
the payers was considered. Previous studies
assessed the cost-effectiveness of liraglutide
versus sitagliptin by applying clinical trial
efficacy data to economic models [13, 26].
Using clinical data from the randomized trial
that compared the efficacy and safety of
liraglutide versus sitagliptin at 26 and
52 weeks, the mean costs per patient to reach
the composite endpoint of A1C \7% with no
hypoglycemia or weight gain were notably
lower for liraglutide than for sitagliptin
($4,225–4,855 lower at 26 weeks and
$5,103–6,523 lower at 52 weeks; 2012 US
dollars) [25].
Our study results imply that improved
glycemic control in clinical practice is related
to lower diabetes-related medical costs among
liraglutide patients compared with sitagliptin
patients. In clinical trials, liraglutide showed
improved sustained body weight reduction and
greater increase in beta cell function [10–12].
These factors, along with dose adjustment and
the cost of the renal monitoring needed for the
use of sitagliptin among patients with renal
impairment [27, 28], may have impacted our
findings. Future research could investigate how
these additional factors are associated with the
economic outcomes of the two treatment
groups.
The interpretation of the results of this study
should be made in light of the limitations
associated with studies based on administrative
claims data. First, the identification of persistent
Table 4 Predicted, adjusted outcomes based on regression analyses
Outcome Rate ratioa (liraglutide versus
sitagliptin)
Predicted outcomes
Liraglutide Sitagliptin Differences P value*
Clinical outcomes
Absolute change in A1C (%
points)
– -0.95 -0.63 -0.31 \0.01
A1C B6.5% 2.00 37% 26% 11% \0.01
A1C\7.0% 1.55 52% 44% 8% \0.01
Economic outcomes
Total diabetes-related costs 0.89 $3,321 $3,720 -$399 0.28
Diabetes-related medical costs 0.56 $1,241 $2,235 -$994 \0.01
Pharmacy costs of anti-
diabetics
1.35 $2,100 $1,556 $544 \0.01
A1C Glycated hemoglobin A1c
*P values were determined from multivariable regression results
a Rate ratio of liraglutide versus sitagliptin was deﬁned as the odds ratio for the A1C goal attainment (A1C B6.5% and A1C
\7.0%), and was deﬁned as cost ratio for the economic outcomes (total diabetes-related costs, diabetes-related medical costs,
and pharmacy costs of anti-diabetics)
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users of medication relied on dispensed
prescriptions, without information of the
actual drug consumption. However, in general,
pharmacy claims are an accurate measure of
prescription drug consumption [29, 30]. Second,
due to the non-experimental nature of the data
and the study design, unmeasured confounders
like prescription bias may influence the results.
Our study considered a wide range of covariates,
including socio-demographic, clinical, and
severity of illness measures to reduce the
residual confounding due to factors like
prescription bias. Third, although clinical trials
determined the efficacy of liraglutide 1.2 mg
separately from 1.8 mg, our study considered
the overall use of liraglutide. It is challenging to
calculate the dose of liraglutide in clinical
practice using claims data since the National
Drug Codes may not completely capture the
clinical practice of dosing and titration, which
may also vary over the considered follow-up
period. Fourth, the database does not have body
mass index or weight information available, so
obesity was identified only by ICD-9-CM codes.
This may result in under-reporting of the
prevalence of obesity. Finally, the
observational nature of the study design does
not allow for causal inferences.
CONCLUSION
In real-world clinical practice in the US,
liraglutide provides significantly greater
improvements in clinical outcomes as
compared with sitagliptin, without any
increase in total diabetes-related costs over
6 months of follow-up. This information could
be used to guide therapeutic decision makers to
make cost-effective decisions for treatment of
patients with T2DM.
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